172 related articles for article (PubMed ID: 20185583)
1. Separation of graft-versus-host disease from graft-versus-leukemia responses by targeting CC-chemokine receptor 7 on donor T cells.
Coghill JM; Carlson MJ; Panoskaltsis-Mortari A; West ML; Burgents JE; Blazar BR; Serody JS
Blood; 2010 Jun; 115(23):4914-22. PubMed ID: 20185583
[TBL] [Abstract][Full Text] [Related]
2. R707, a fully human antibody directed against CC-chemokine receptor 7, attenuates xenogeneic acute graft-versus-host disease.
Fowler KA; Vasilieva V; Ivanova E; Rimkevich O; Sokolov A; Abbasova S; Kim E; Coghill JM
Am J Transplant; 2019 Jul; 19(7):1941-1954. PubMed ID: 30748092
[TBL] [Abstract][Full Text] [Related]
3. The Ex Vivo Treatment of Donor T Cells with Cosalane, an HIV Therapeutic and Small-Molecule Antagonist of CC-Chemokine Receptor 7, Separates Acute Graft-versus-Host Disease from Graft-versus-Leukemia Responses in Murine Hematopoietic Stem Cell Transplantation Models.
Fowler KA; Li K; Whitehurst CB; Bruce DW; Moorman NJ; Aubé J; Coghill JM
Biol Blood Marrow Transplant; 2019 Jun; 25(6):1062-1074. PubMed ID: 30668984
[TBL] [Abstract][Full Text] [Related]
4. CCR7 guides migration of mesenchymal stem cell to secondary lymphoid organs: a novel approach to separate GvHD from GvL effect.
Li H; Jiang Y; Jiang X; Guo X; Ning H; Li Y; Liao L; Yao H; Wang X; Liu Y; Zhang Y; Chen H; Mao N
Stem Cells; 2014 Jul; 32(7):1890-903. PubMed ID: 24496849
[TBL] [Abstract][Full Text] [Related]
5. Depletion of host CCR7(+) dendritic cells prevented donor T cell tissue tropism in anti-CD3-conditioned recipients.
He W; Racine JJ; Johnston HF; Li X; Li N; Cassady K; Liu C; Deng R; Martin P; Forman S; Zeng D
Biol Blood Marrow Transplant; 2014 Jul; 20(7):920-8. PubMed ID: 24691220
[TBL] [Abstract][Full Text] [Related]
6. Altered T-cell entry and egress in the absence of Coronin 1A attenuates murine acute graft versus host disease.
Fulton LM; Taylor NA; Coghill JM; West ML; Föger N; Bear JE; Baldwin AS; Panoskaltsis-Mortari A; Serody JS
Eur J Immunol; 2014 Jun; 44(6):1662-71. PubMed ID: 24752751
[TBL] [Abstract][Full Text] [Related]
7. Donor T cells primed on leukemia lysate-pulsed recipient APCs mediate strong graft-versus-leukemia effects across MHC barriers in full chimeras.
Ghosh A; Koestner W; Hapke M; Schlaphoff V; Länger F; Baumann R; Koenecke C; Cornberg M; Welte K; Blazar BR; Sauer MG
Blood; 2009 Apr; 113(18):4440-8. PubMed ID: 19182207
[TBL] [Abstract][Full Text] [Related]
8. Graft-versus-host disease is enhanced by selective CD73 blockade in mice.
Wang L; Fan J; Chen S; Zhang Y; Curiel TJ; Zhang B
PLoS One; 2013; 8(3):e58397. PubMed ID: 23520507
[TBL] [Abstract][Full Text] [Related]
9. Beta2 integrins separate graft-versus-host disease and graft-versus-leukemia effects.
Liang Y; Liu C; Djeu JY; Zhong B; Peters T; Scharffetter-Kochanek K; Anasetti C; Yu XZ
Blood; 2008 Jan; 111(2):954-62. PubMed ID: 17928532
[TBL] [Abstract][Full Text] [Related]
10. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
Xia G; Truitt RL; Johnson BD
Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-17-92 controls T-cell responses in graft-versus-host disease and leukemia relapse in mice.
Wu Y; Heinrichs J; Bastian D; Fu J; Nguyen H; Schutt S; Liu Y; Jin J; Liu C; Li QJ; Xia C; Yu XZ
Blood; 2015 Sep; 126(11):1314-23. PubMed ID: 26138686
[TBL] [Abstract][Full Text] [Related]
12. Abrogation of donor T-cell IL-21 signaling leads to tissue-specific modulation of immunity and separation of GVHD from GVL.
Hanash AM; Kappel LW; Yim NL; Nejat RA; Goldberg GL; Smith OM; Rao UK; Dykstra L; Na IK; Holland AM; Dudakov JA; Liu C; Murphy GF; Leonard WJ; Heller G; van den Brink MR
Blood; 2011 Jul; 118(2):446-55. PubMed ID: 21596854
[TBL] [Abstract][Full Text] [Related]
13. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.
Giver CR; Montes RO; Mittelstaedt S; Li JM; Jaye DL; Lonial S; Boyer MW; Waller EK
Biol Blood Marrow Transplant; 2003 Oct; 9(10):616-32. PubMed ID: 14569558
[TBL] [Abstract][Full Text] [Related]
14. Preimplantation factor reduces graft-versus-host disease by regulating immune response and lowering oxidative stress (murine model).
Azar Y; Shainer R; Almogi-Hazan O; Bringer R; Compton SR; Paidas MJ; Barnea ER; Or R
Biol Blood Marrow Transplant; 2013 Apr; 19(4):519-28. PubMed ID: 23266739
[TBL] [Abstract][Full Text] [Related]
15. ATG5-Dependent Autophagy Uncouples T-cell Proliferative and Effector Functions and Separates Graft-versus-Host Disease from Graft-versus-Leukemia.
Oravecz-Wilson K; Rossi C; Zajac C; Sun Y; Li L; Decoville T; Fujiwara H; Kim S; Peltier D; Reddy P
Cancer Res; 2021 Feb; 81(4):1063-1075. PubMed ID: 33277367
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect.
Choi J; Cooper ML; Alahmari B; Ritchey J; Collins L; Holt M; DiPersio JF
PLoS One; 2014; 9(10):e109799. PubMed ID: 25289677
[TBL] [Abstract][Full Text] [Related]
17. IL-22 deficiency in donor T cells attenuates murine acute graft-versus-host disease mortality while sparing the graft-versus-leukemia effect.
Couturier M; Lamarthée B; Arbez J; Renauld JC; Bossard C; Malard F; Bonnefoy F; Mohty M; Perruche S; Tiberghien P; Saas P; Gaugler B
Leukemia; 2013 Jul; 27(7):1527-37. PubMed ID: 23399894
[TBL] [Abstract][Full Text] [Related]
18. Treatment of donor mice with an alpha beta T-cell receptor monoclonal antibody induces prolonged T-cell nonresponsiveness and effectively prevents lethal graft-versus-host disease in murine recipients of major histocompatibility complex (MHC)-matched and MHC-mismatched donor marrow grafts.
Drobyski WR; Majewski D
Blood; 1996 Jun; 87(12):5355-69. PubMed ID: 8652851
[TBL] [Abstract][Full Text] [Related]
19. Targeting Interleukin-2-Inducible T-Cell Kinase (ITK) Differentiates GVL and GVHD in Allo-HSCT.
Mammadli M; Huang W; Harris R; Sultana A; Cheng Y; Tong W; Pu J; Gentile T; Dsouza S; Yang Q; Bah A; August A; Karimi M
Front Immunol; 2020; 11():593863. PubMed ID: 33324410
[TBL] [Abstract][Full Text] [Related]
20. Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation.
Betts BC; Bastian D; Iamsawat S; Nguyen H; Heinrichs JL; Wu Y; Daenthanasanmak A; Veerapathran A; O'Mahony A; Walton K; Reff J; Horna P; Sagatys EM; Lee MC; Singer J; Chang YJ; Liu C; Pidala J; Anasetti C; Yu XZ
Proc Natl Acad Sci U S A; 2018 Feb; 115(7):1582-1587. PubMed ID: 29382747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
